ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
인크레틴계 의약품 시장 규모는 향후 수년간 강력한 성장이 전망됩니다. 2029년에는 CAGR 7.2%로 성장할 전망이며, 367억 달러로 성장이 예측됩니다. 예측 기간 동안 예상되는 성장은 조제요법 채택 증가, 체중관리 및 비만에 따른 당뇨병에 대한 중점적인 대처 증가, 맞춤형 의료 및 동반진단의 진보, 저침습 약물전달법에 대한 수요 증가, 합병증의 부담이 큰 고령화 등에 기인할 것으로 보입니다. 예측 기간 동안 예측되는 주요 동향으로는 비만 치료 프로그램에 인크레틴 제제를 삽입하고 대사전귀를 개선하기 위한 이중 아고니스트 및 트리플 아고니스트의 출현, 맞춤형 모니터링을 위한 인크레틴 요법과 디지털 헬스 도구의 통합, 고도의 당뇨병 관리를 위한 단제 요법보다 병용 요법의 우위성, 투여 빈도를 줄이기 위한 장시간 작용형 주 1회 주사에 대한 관심 증가 등이 있습니다.
2형 당뇨병의 유병률 증가는 향후 수년간 인크레틴계 의약품 시장의 성장을 견인할 것으로 예측됩니다. 제2형 당뇨병은 인슐린 저항성과 인슐린 분비 저하로 혈당이 상승하는 만성 대사질환입니다. 이 병태는 주로 식생활의 혼란이나 운동 부족 등의 요인에 의해 발생하며, 이러한 요인들이 인슐린 저항성을 조장하고 혈당을 조절하는 신체의 능력을 손상시킵니다. 인크레틴계 의약품은 식후 인슐린 분비를 촉진하고 글루카곤의 생성을 감소시킴으로써 혈당을 낮추고 제2형 당뇨병 관리에 도움을 줍니다. 또한 위 배출을 늦추고 식욕을 억제함으로써 더 나은 포도당 컨트롤과 체중 감소를 돕습니다. 예를 들어 2024년 6월 영국의 정부기관인 국민보건서비스(National Health Service)는 2023년에는 잉글랜드에서 새롭게 약 54만 9000명이 제2형 당뇨병이 발병했으며 당뇨병 예비군의 총수는 360만 명 이상으로 증가했다고 보고했습니다. 따라서 제2형 당뇨병의 유병률 상승이 인크레틴계 의약품 시장의 성장을 촉진하고 있습니다.
인크레틴계 의약품 시장의 주요 기업은 2형 당뇨병의 보다 효과적이고 환자 친화적인 치료법을 제공하기 위해 제네릭 의약품 개발에 주력하고 있습니다. 제네릭 의약품은 선발 의약품과 동일한 유효 성분, 강도, 제형, 투여 경로를 포함하지만 브랜드명을 붙이지 않고 화학명으로 판매됩니다. 예를 들면, 2024년 12월, 영국에 본사를 둔 제약회사 히쿠마 파마슈티컬스 PLC는, 미국에서 최초의 빅토자(리라글루치드) 주사제 6 mg/mL의 제네릭 의약품을 발매했습니다. 본 약제는 10세 이상 성인 및 소아의 제2형 당뇨병 환자를 대상으로 식이요법 및 운동요법의 보조로서 혈당조절을 개선하는 치료제이며, GLP-1 제제의 공급부족이 지속되는 가운데 보다 저렴한 치료 선택지를 제공하는 것입니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향 및 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁 및 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석 및 전략 분석 프레임워크
세계의 인크레틴계 의약품 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인 및 억제요인)
최종 이용 산업의 분석
세계의 인크레틴계 의약품 시장 : 성장률 분석
세계의 인크레틴계 의약품 시장 실적 : 규모 및 성장(2019-2024년)
세계의 인크레틴계 의약품 시장 예측 : 규모 및 성장(2024-2029년, 2034년)
세계의 인크레틴계 의약품 : 전체 시장 규모(TAM)
제6장 시장 세분화
세계의 인크레틴계 의약품 시장 : 유형별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
글루카곤 유사 펩티드-1 수용체(GLP-1) 작용제
디펩티딜 펩티다아제-4(DPP-4) 억제제
세계의 인크레틴계 의약품 시장 : 투여 경로별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
오랄
주사제
세계의 인크레틴계 의약품 시장 : 유통 채널별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
병원 약국
소매 약국
온라인 약국
세계의 인크레틴계 의약품 시장 : 용도별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
2형 당뇨병
비만
기타 용도
세계의 인크레틴계 의약품 시장 : 글루카곤 유사 펩티드-1 수용체(GLP-1) 작용제 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
엑세나티드
리라글루티드
듀라글루티드
세마글루티드
릭시세나티드
알비글루티드
세계의 인크레틴계 의약품 시장 : 디펩티딜 펩티다아제-4(DPP-4) 억제제 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
시타글립틴
사그립틴
리나글립틴
알로글립틴
빌더 그립틴
제7장 지역별 및 국가별 분석
세계의 인크레틴계 의약품 시장 : 지역별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
세계의 인크레틴계 의약품 시장 : 국가별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도 및 기업 프로파일
인크레틴계 의약품 시장 : 경쟁 구도
인크레틴계 의약품 시장 : 기업 프로파일
Pfizer Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Johnson & Johnson : 개요, 제품 및 서비스, 전략 및 재무 분석
Roche Holding AG : 개요, 제품 및 서비스, 전략 및 재무 분석
AbbVie Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Bristol-Myers Squibb Company : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
AstraZeneca PLC
Novartis AG
GlaxoSmithKline plc
Eli Lilly and Company
Takeda Pharmaceutical Company Limited
Amgen Inc.
Novo Nordisk A/S
Viatris
Boehringer Ingelheim GmbH
Astellas Pharma Inc.
Daiichi Sankyo Company Limited
Sun Pharmaceutical Industries Ltd.
Sumitomo Dainippon Pharma Co. Ltd.
Hikma Pharmaceuticals PLC
Lupin Limited
제32장 세계 시장 경쟁 벤치마킹 및 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문 및 전략
인크레틴계 의약품 시장(2029년) : 새로운 기회를 제공하는 국가
인크레틴계 의약품 시장(2029년) : 새로운 기회를 제공하는 부문
인크레틴계 의약품 시장(2029년) : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
AJY
영문 목차
영문목차
Incretin-based drugs are medications used to manage type 2 diabetes by enhancing the effects of incretin hormones, which stimulate insulin release after meals. These drugs aid in controlling blood sugar levels, suppressing appetite, and supporting weight loss. They also help prevent sharp increases in blood glucose and generally have a low risk of causing severe hypoglycemia.
The primary types of incretin-based drugs include glucagon-like peptide-1 receptor (GLP-1) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors. GLP-1 receptor agonists imitate the natural GLP-1 hormone to boost insulin secretion, reduce glucagon levels, delay gastric emptying, and lower blood sugar in individuals with type 2 diabetes and obesity. These drugs are administered via different routes, such as oral and injectable forms, and are distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies, for applications such as type 2 diabetes, obesity, and other related conditions.
The incretin-based drugs market research report is one of a series of new reports from The Business Research Company that provides incretin-based drugs market statistics, including the incretin-based drugs industry global market size, regional shares, competitors with the incretin-based drugs market share, detailed incretin-based drugs market segments, market trends, opportunities, and any further data you may need to thrive in the incretin-based drugs industry. This incretin-based drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The incretin-based drugs market size has grown strongly in recent years. It will grow from $25.89 billion in 2024 to $27.83 billion in 2025 at a compound annual growth rate (CAGR) of 7.5%. The growth during the historic period can be attributed to the increasing global prevalence of type 2 diabetes, the launch of GLP-1 receptor agonists such as exenatide and liraglutide, substantial investments in research and development, favorable regulatory approvals for DPP-4 and GLP-1 medications, a transition from insulin and sulfonylureas to newer drug classes, and the introduction of once-weekly injectable formulations.
The incretin-based drugs market size is expected to see strong growth in the next few years. It will grow to $36.70 billion in 2029 at a compound annual growth rate (CAGR) of 7.2%. The growth expected in the forecast period can be attributed to the rising adoption of fixed-dose combination therapies, increased emphasis on weight management and diabetes associated with obesity, advancements in personalized medicine and companion diagnostics, growing demand for minimally invasive drug delivery methods, and an aging population with a higher burden of comorbidities. Key trends projected for the forecast period include the incorporation of incretin drugs into obesity treatment programs, the emergence of dual and triple agonists to improve metabolic outcomes, the integration of digital health tools with incretin therapies for personalized monitoring, the predominance of combination therapies over monotherapies for advanced diabetes management, and a growing focus on long-acting weekly injections to reduce dosing frequency.
The increasing prevalence of type 2 diabetes mellitus is expected to drive the growth of the incretin-based drugs market in the coming years. Type 2 diabetes mellitus is a chronic metabolic condition marked by insulin resistance and reduced insulin secretion, resulting in elevated blood glucose levels. This condition is primarily caused by factors such as poor diet and physical inactivity, which contribute to insulin resistance and impair the body's ability to regulate blood sugar. Incretin-based drugs help manage type 2 diabetes by enhancing insulin secretion after meals and decreasing glucagon production, thereby lowering blood sugar levels. They also slow gastric emptying and suppress appetite, supporting better glucose control and weight reduction. For example, in June 2024, the National Health Service, a UK-based government organization, reported that in 2023 approximately 549,000 additional individuals in England were at risk of developing type 2 diabetes, increasing the total number of people with pre-diabetes to over 3.6 million-a rise of nearly 20% from 2022. Hence, the rising prevalence of type 2 diabetes mellitus is fueling the growth of the incretin-based drugs market.
Leading companies in the incretin-based drugs market are concentrating on developing generic drug versions to provide more effective and patient-friendly treatment options for type 2 diabetes. A generic drug contains the same active ingredients, strength, dosage form, and route of administration as its brand-name counterpart but is marketed under its chemical name without branding. For example, in December 2024, Hikma Pharmaceuticals PLC, a pharmaceutical company based in the UK, launched the first generic version of Victoza (liraglutide) injection, 6 mg/mL, in the United States. The drug received approval from the Food and Drug Administration (FDA) and is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes, offering a more affordable treatment option amid ongoing shortages of GLP-1 medications.
In July 2024, Roche, a pharmaceutical company headquartered in Switzerland, acquired Carmot Therapeutics for approximately $2.7 billion. This strategic acquisition is aimed at enhancing Roche's presence in the rapidly expanding obesity and metabolic disease market by incorporating Carmot's innovative injectable and oral therapies into its pharmaceuticals division. Carmot Therapeutics is a U.S.-based clinical-stage biotechnology company specializing in obesity and diabetes, with a strong focus on incretin-based therapies, including GLP-1 and GIP receptor agonists.
Major players in the incretin-based drugs market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Amgen Inc., Novo Nordisk A/S, Viatris, Boehringer Ingelheim GmbH, Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd., Sumitomo Dainippon Pharma Co. Ltd., Hikma Pharmaceuticals PLC, Lupin Limited, Mitsubishi Tanabe Pharma Corporation.
North America was the largest region in the incretin-based drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in incretin-based drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the incretin-based drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The incretin-based drugs market consists of sales of dual or multi-agonists, glucagon receptor co-agonists, and fixed-dose combination drugs. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the drugs, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the drugs.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Incretin-Based Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on incretin-based drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for incretin-based drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The incretin-based drugs market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Incretin-Based Drugs Market Characteristics
3. Incretin-Based Drugs Market Trends And Strategies
4. Incretin-Based Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Incretin-Based Drugs Growth Analysis And Strategic Analysis Framework
5.1. Global Incretin-Based Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Incretin-Based Drugs Market Growth Rate Analysis
5.4. Global Incretin-Based Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Incretin-Based Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Incretin-Based Drugs Total Addressable Market (TAM)
6. Incretin-Based Drugs Market Segmentation
6.1. Global Incretin-Based Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Glucagon-Like Peptide-1 Receptor (GLP-1) Agonists
Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
6.2. Global Incretin-Based Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral
Injectable
6.3. Global Incretin-Based Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
6.4. Global Incretin-Based Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Type 2 Diabetes
Obesity
Other Applications
6.5. Global Incretin-Based Drugs Market, Sub-Segmentation Of Glucagon-Like Peptide-1 Receptor (GLP-1) Agonists, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Exenatide
Liraglutide
Dulaglutide
Semaglutide
Lixisenatide
Albiglutide
6.6. Global Incretin-Based Drugs Market, Sub-Segmentation Of Dipeptidyl Peptidase-4 (DPP-4) Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Sitagliptin
Saxagliptin
Linagliptin
Alogliptin
Vildagliptin
7. Incretin-Based Drugs Market Regional And Country Analysis
7.1. Global Incretin-Based Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Incretin-Based Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Incretin-Based Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Incretin-Based Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Incretin-Based Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Incretin-Based Drugs Market
9.1. China Incretin-Based Drugs Market Overview
9.2. China Incretin-Based Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Incretin-Based Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Incretin-Based Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Incretin-Based Drugs Market
10.1. India Incretin-Based Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Incretin-Based Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Incretin-Based Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Incretin-Based Drugs Market
11.1. Japan Incretin-Based Drugs Market Overview
11.2. Japan Incretin-Based Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Incretin-Based Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Incretin-Based Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Incretin-Based Drugs Market
12.1. Australia Incretin-Based Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Incretin-Based Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Incretin-Based Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Incretin-Based Drugs Market
13.1. Indonesia Incretin-Based Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Incretin-Based Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Incretin-Based Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Incretin-Based Drugs Market
14.1. South Korea Incretin-Based Drugs Market Overview
14.2. South Korea Incretin-Based Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Incretin-Based Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Incretin-Based Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Incretin-Based Drugs Market
15.1. Western Europe Incretin-Based Drugs Market Overview
15.2. Western Europe Incretin-Based Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Incretin-Based Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Incretin-Based Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Incretin-Based Drugs Market
16.1. UK Incretin-Based Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Incretin-Based Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Incretin-Based Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Incretin-Based Drugs Market
17.1. Germany Incretin-Based Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Incretin-Based Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Incretin-Based Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Incretin-Based Drugs Market
18.1. France Incretin-Based Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Incretin-Based Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Incretin-Based Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Incretin-Based Drugs Market
19.1. Italy Incretin-Based Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Incretin-Based Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Incretin-Based Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Incretin-Based Drugs Market
20.1. Spain Incretin-Based Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Incretin-Based Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Incretin-Based Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Incretin-Based Drugs Market
21.1. Eastern Europe Incretin-Based Drugs Market Overview
21.2. Eastern Europe Incretin-Based Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Incretin-Based Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Incretin-Based Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Incretin-Based Drugs Market
22.1. Russia Incretin-Based Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Incretin-Based Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Incretin-Based Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Incretin-Based Drugs Market
23.1. North America Incretin-Based Drugs Market Overview
23.2. North America Incretin-Based Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Incretin-Based Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Incretin-Based Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Incretin-Based Drugs Market
24.1. USA Incretin-Based Drugs Market Overview
24.2. USA Incretin-Based Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Incretin-Based Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Incretin-Based Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Incretin-Based Drugs Market
25.1. Canada Incretin-Based Drugs Market Overview
25.2. Canada Incretin-Based Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Incretin-Based Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Incretin-Based Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Incretin-Based Drugs Market
26.1. South America Incretin-Based Drugs Market Overview
26.2. South America Incretin-Based Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Incretin-Based Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Incretin-Based Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Incretin-Based Drugs Market
27.1. Brazil Incretin-Based Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Incretin-Based Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Incretin-Based Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Incretin-Based Drugs Market
28.1. Middle East Incretin-Based Drugs Market Overview
28.2. Middle East Incretin-Based Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Incretin-Based Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Incretin-Based Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Incretin-Based Drugs Market
29.1. Africa Incretin-Based Drugs Market Overview
29.2. Africa Incretin-Based Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Incretin-Based Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Incretin-Based Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Incretin-Based Drugs Market Competitive Landscape And Company Profiles
